A new survey by the British Medical Journal reveals a dramatic increase in the number of patients prescribed medusa drugs to treat symptoms of post-traumatic stress disorder.
According to the study, published in the journal BMJ Open, the number for 2017 rose from 10,822 in 2016 to 11,906 in 2017.
In all, more than 3.6 million people received the drugs, with the majority of them prescribed to treat post-trauma-related stress disorders such as post-surgical anxiety, post-concussion syndrome, postpartum depression, post traumatic stress disorder (PTSD) and post traumatic exposure disorder (POST).
The drug was also prescribed for other conditions including irritable bowel syndrome, depression and schizophrenia.
“The use of the drug has become widespread as the condition has been linked to the use of pharmaceuticals to treat PTSD in the UK and other countries,” said Dr Stephen Denton, an associate professor at King’s College London and the author of the study.
“But it has also become a trend in the US, which has seen some of the drugs prescribed to the British have caused a spike in sales, with some people having been prescribed the drugs for many years.”
So we are seeing this growth in prescription of medusa,” he added.”
It’s not just an epidemic of drug use, but it’s also an epidemic in the United Kingdom as well.
“If you go into the drugstore and see that the number one item is the medusa, you would be forgiven for thinking that’s just a trend of the past.”
There is now a big number of people who are being prescribed these drugs for PTSD, so it is becoming a big trend.
“The increase in prescribing of medusas came as a surprise to Dr Andrew Worsley, an NHS medical director at Leeds General Infirmary.”
We’re in the middle of an outbreak of this in the NHS, which is a really worrying development,” he said.”
Medusas are used in the treatment of some of these other conditions and people have been prescribed them for years and years.
It is very worrying that the NHS is not doing more to support and promote its use and availability,” he continued.”
The number of prescriptions is rising, which indicates there is a big demand for the drug.”
“It is very worrying that the NHS is not doing more to support and promote its use and availability,” he continued.
Dr Worsleys study found that, despite a long history of prescribing medusa, the use was not rising in the way doctors wanted it to.
“While the number prescribing medusa in the past has been relatively high, it was not at the level we would like,” he explained.
“We do want to see more of this, and more people getting the medication.”
But Dr WorsLEY believes that more can be done to support the use and development of meduses.
“I think it is important that we make sure we have the right prescribing guidelines and policies in place, so that we can ensure that these medications are prescribed appropriately,” he concluded.